Loading
Life sciences · Journal article
Science · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is now widely recognized as a chronic progressive condition. The altered biological mechanisms that cause obesity frequently require long-term treatment, including pharmacotherapies or bariatric surgery. In recent decades, the pathophysiology of obesity has been understood to an extent that obesity management medication (OMM) discovery could be rationally pursued. Advances in defining the regulation of food intake and energy expenditure by molecular communication from peripheral organs to the brain led to the development of OMMs that appear capable of safely achieving scalable and sustained body weight loss. However, side effects, heterogeneous treatment responses, long-term metabolic adaptations, adherence, and other factors may limit the use of existing OMMs and justify the development of additional medications to improve the health of people living with obesity.